Phase 1 Double-Blinded, Randomized, Placebo Controlled Safety and Early Efficacy Trial of Cryopreserved Cord Blood Derived T-Regulatory Cell Infusions (CK0802) In The Treatment Of COVID-19 Induced Acute Respiratory Distress Syndrome (ARDS)
Latest Information Update: 14 Mar 2022
At a glance
- Drugs CK 0802 (Primary)
- Indications Adult respiratory distress syndrome; COVID 2019 infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms RESOLVE
- Sponsors Cellenkos
- 08 Mar 2022 Status changed from active, no longer recruiting to completed.
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 04 Nov 2021 According to a Cellenkos media release, the results will be presented during an oral presentation at the annual meeting of the ASH.
Most Recent Events
Trial Overview
Purpose
This Phase I, placebo-controlled study is designed to assess the safety and preliminary efficacy of cryopreserved cord blood-derived T-regulatory cells (CK0802) for treatment of COVID-19 associated acute respiratory distress syndrome (hospitalized patient population).
Primary Endpoints
Regimen related ≥ grade 3 toxicity within 48 hours of first infusion
description: Regimen related ≥ grade 3 toxicity within 48 hours of first infusion (DLT)
time_frame: 48 hours
28-day treatment success, defined as S28 [ Time Frame: 28 days]
Alive and not intubated 28 days after the date of first infusion
Other Endpoints
Time to extubation
description: Time to extubation
time_frame: 28 days
Oxygenation improvement
description: Oxygenation requirement (PaO2/FiO2) change between day 0 and day +11
time_frame: 11 days
Ventilator free days
description: Ventilator free days measured at day 28
time_frame: 28 days
Organ failure free days
description: Organ failure free days measured at day 28
time_frame: 28 days
ICU free days
description: ICU free days measured at day 28
time_frame: 28 days
All-cause mortality
description: All-cause mortality at day 28
time_frame: 28 days [1]
Diseases Treated
Indication | Qualifiers | Patient Segments |
---|---|---|
Adult respiratory distress syndrome | treatment | - |
COVID 2019 infections | treatment | - |
Subjects
- Subject Type patients
-
Number
Planned: 45
Actual: 45
- Sex male & female
- Age Group 21-85(median 60) years; adult; elderly
Patient Inclusion Criteria
- Documented to have an RT-PCR-based diagnosis of SARS-CoV-2 infection by RT-PCR - Moderate-to-severe ARDS as defined by the Berlin Criteria: ratio of partial pressure of arterial oxygen (PaO2) to the fraction of inspired oxygen (FiO2) of 200 mm Hg or less assessed with a positive end-expiratory pressure (PEEP) of >5 cm H2O. - Intubated for less than 120 hours - Age ≥18 years - Ability to provide informed consent or duly appointment health care proxy with the authority to provide informed consent.
Patient Exclusion Criteria
1. In the opinion of the investigator, unlikely to survive for >48 hours from screening. 2. Any physical examination findings and/or history of any illness that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the patient by their participation in the study. 3. Currently receiving extracorporeal membrane oxygenation (ECMO) or high frequency oscillatory ventilation (HFOV). 4. Females who are pregnant. 5. Patients with active bacteremia at start of therapy enrollment or concurrently active moderate to severe other infectious which in the opinion of the investigator may possibly affect the safety of CK0802 treatment. 6. Patients who have been intubated for more than 120 hours. 7. Known hypersensitivity to DMSO or to porcine or bovine protein. 8. Any end-stage organ disease which in the opinion of the investigator may possibly affect the safety of CK0802 treatment. 9. High dose steroids. 10. Receiving an investigational cellular therapy agent.
Trial Details
Identifiers
Identifier | Owner |
---|---|
NCT04468971 | ClinicalTrials.gov: US National Institutes of Health |
CK0802-501-1 | - |
Organisations
- Sponsors Cellenkos
- Affiliations Cellenkos
Trial Dates
-
Initiation Dates
Planned : 30 Aug 2020
Actual : 29 Sep 2020
-
Primary Completion Dates
Planned : 30 Sep 2021
Actual : 22 Oct 2021
-
End Dates
Planned : 30 Sep 2021
Actual : 22 Oct 2021
Other Details
- Design double-blind; multicentre; parallel; prospective; randomised
- Phase of Trial Phase I
- Location USA
- Focus Adverse reactions; Therapeutic Use
Interventions
Drugs | Route | Formulation |
---|---|---|
CK 0802Primary Drug | Intravenous | Infusion |
Arm 2
CK0802: 1x10^8 cells
Biological: CK0802 (Cryopreserved, off the shelf, cord blood derived T regulatory cells)
Arm 3
CK0802: 3x10^8 cells
Biological: CK0802 (Cryopreserved, off the shelf, cord blood derived T regulatory cells)
Arm 1
Excipient
Drug: Placebo (Expicient)
Results
Therapeutic efficacy
In the phase I RESOLVE trial, treatment with CK 0802 showed promising efficacy. Median time to extubation from first infusion was 10.5 [2-46] days and median ventilator free days at day 28 was 12 [0-26]days. Time to extubation from first infusion was 10.5 days (2-46) and at day 28 the ventilator free days were 12 (0-26). The estimated day 28 overall survival was 78.6% with the following breakdown according to the co-variates: i) age>60 yrs =77.5% vs. age<60yrs=79.9%; ii) female=85.7% vs male=73.7%; iii) on vasopressor=65.8% vs. 77.8%; iv) on hemodialysis=75% vs. 79%. Duration of intubation to enrollment had no impact on 28d survival. At baseline, 14 patients were positive for both HLA I and HLA II antibodies (Abs); 3 patients positive for HLA I Ab only, and 9 positive for HLA II Ab only. In 20 paired samples collected on day 0 and day 28, HLA I Ab and HLA II Ab seroconversion was observed in 4 and 1 patient, respectively [2] .
Adverse events
In the phase I RESOLVE trial, treatment with CK 0802 was found to be safe. No treatment related SAEs were reported [2] .
Publications
-
Gladstone DE, Howard C, Lyu M-A, Mock J, Adams D, Gibbs K, et al. Randomized, Multi-Center, Double-Blinded, Placebo Controlled Safety and Early Efficacy Trial of Cryopreserved Cord Blood Derived T-Regulatory Cell Infusions (CK0802) in the Treatment of COVID-19 Induced ARDS. (RESOLVE Trial). ASH-Hem-2021 2021; abstr. 828.
Available from: URL: https://ash.confex.com/ash/2021/webprogram/Paper153616.html
Trial Centres
Investigators
Investigator | Centre Name | Trial Centre Country |
---|---|---|
Carlos Reyes-Vidal
212-305-4921 csr52@cumc.columbia.edu
show details
|
Columbia University | USA |
Christopher Howard, MD | Baylor College of Medicine, St Luke's Hospital | USA |
Darryl Adams | Columbia University | USA |
Douglas Gladstone, MD | Johns Hopkins Hospital | USA |
Jason Mock, MD, PhD | University of North Carolina | USA |
Joby Mathew
jmathe27@jhmi.edu
show details
|
Johns Hopkins Hospital | USA |
Kevin Harris | Wake Forest University | USA |
Pinchie Onyango
336-716-6591 ponyango@wakehealth.edu
show details
|
Wake Forest University | USA |
Rafael Cardenas
Rafael.CardenasCastillo@bcm.edu
show details
|
Baylor College of Medicine, St Luke's Hospital | USA |
Tara Sadeghi
7138064787
show details
tara.sadeghi@cellenkosinc.com |
, Cellenkos Inc. |
-
|
Centres
Centre Name | Location | Trial Centre Country |
---|---|---|
- |
-
|
-
|
Baylor College of Medicine, St Luke's Hospital | Houston, Texas | USA |
Cellenkos Inc. |
-
|
-
|
Columbia University | New York, New York | USA |
Johns Hopkins Hospital | Baltimore, Maryland | USA |
University of North Carolina | Chapel Hill, North Carolina | USA |
Wake Forest University | Winston-Salem, North Carolina | USA |
Trial History
Event Date | Event Type | Comment |
---|---|---|
14 Mar 2022 | Other trial event | Last checked against ClinicalTrials.gov record. Updated 14 Mar 2022 |
08 Mar 2022 | Status change - completed | Status changed from active, no longer recruiting to completed. Updated 14 Mar 2022 |
14 Dec 2021 | Results | Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition Updated 27 Jan 2022 |
04 Nov 2021 | Other trial event | According to a Cellenkos media release, the results will be presented during an oral presentation at the annual meeting of the ASH. Updated 16 Nov 2021 |
21 Jun 2021 | Status change - active, no longer recruiting | Status changed from recruiting to active, no longer recruiting. Updated 24 Jun 2021 |
29 Sep 2020 | Status change - recruiting | Status changed from not yet recruiting to recruiting. Updated 05 Oct 2020 |
16 Jul 2020 | Other trial event | New source identified and integrated:(ClinicalTrials.gov: US National Institutes of Health: NCT04468971). Updated 16 Jul 2020 |
10 Jul 2020 | Status change - not yet recruiting | Status changed from planning to not yet recruiting. Updated 16 Jul 2020 |
06 Jul 2020 | Other trial event | According to a Cellenkos media release, this trial is anticipated to start in the third quarter of 2020. Updated 08 Jul 2020 |
02 Jun 2020 | Other trial event | According to a Cellenkos media release, Dr Siddhartha Mukherjee (MD, PhD, Columbia University, New York) is the scientific advisor and collaborator on this multi-center clinical trial.According to him planned correlative assays during the clinical trial will provide insights into the mechanism of action of CK0802 and its relation to clinical outcomes. Updated 08 Jun 2020 |
02 Jun 2020 | Other trial event | According to a Cellenkos media release, the US Food and Drug Administration (FDA) has cleared the way to initiate this Phase 1 clinical trial of CK0802 (Cryopreserved Cord Blood Derived T-Regulatory Cells) for treatment of COVID-19 associated acute respiratory distress syndrome (ARDS). Updated 08 Jun 2020 |
18 Mar 2020 | New trial record | New trial record Updated 18 Mar 2020 |
17 Mar 2020 | Other trial event | According to a Cellenkos media release, the company has submitted a clinical development proposal to the Biomedical Advanced Research and Development Authority (BARDA) to start this study. Updated 18 Mar 2020 |
Table of Contents
References
-
ClinicalTrials.gov: US National Institutes of Health. Trial-Reg 2023;.
Available from: URL: http://clinicaltrials.gov -
Gladstone DE, Howard C, Lyu M-A, Mock J, Adams D, Gibbs K, et al. Randomized, Multi-Center, Double-Blinded, Placebo Controlled Safety and Early Efficacy Trial of Cryopreserved Cord Blood Derived T-Regulatory Cell Infusions (CK0802) in the Treatment of COVID-19 Induced ARDS. (RESOLVE Trial). ASH-Hem-2021 2021; abstr. 828.
Available from: URL: https://ash.confex.com/ash/2021/webprogram/Paper153616.html -
Cellenkos. Cellenkos(R) Inc. Announces FDA Clearance to Initiate Phase 1 Double- Blinded, Randomized, Placebo-Controlled Trial of Cryopreserved Cord Blood-Derived T-Regulatory Cells (CK0802) for Treatment of COVID-19 Associated Acute Respiratory Distress Syndrome. Media-Rel 2020;.
Media Release -
Johns Hopkins University. Johns Hopkins Reports Promising Clinical Data in COVID-19 ARDS Treated with Cellenkos' Cord Blood T-Regulatory Cells. Media-Rel 2020;.
Media Release -
Cellenkos. Cellenkos Inc. Focuses on the Development of Cell-Therapy for Treatment of COVID-19 Mediated Acute Respiratory Distress Syndrome (CoV-ARDS). Media-Rel 2020;.
Media Release -
Cellenkos. Cellenkos(Rm) Inc. Secures $15 Million Series A Financing to Accelerate the Development of Transformation Cell-Based Therapies. Media-Rel 2021;.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG